{
    "nct_id": "NCT04943536",
    "official_title": "Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer",
    "inclusion_criteria": "* Patients with biopsy proven localized prostate cancer in whom prostate radiation and ADT is appropriate therapy (such as Intermediate Risk localized prostate cancer)\n* Patients must have at least 1 MRI detected; biopsy proven prostate cancer.\n* Patients diagnosed as one of the following:\n\n  1. National Comprehensive Cancer Network (NCCN) intermediate risk prostate cancer, OR\n  2. NCCN high risk prostate cancer due to Gleason Grade 4 or 5 AND refuses to receive systemic ADT, OR\n  3. NCCN high risk prostate cancer due to Prostate Specific Antigen (PSA) > 20 AND refuses to receive systemic ADT.\n* Age >18 years.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* NCCN high risk patients eligible for treatment with systemic ADT who do not refuse systemic ADT.\n* Patients receiving prior radiotherapy or surgery for prostate cancer.\n* Patients receiving prior or ongoing ADT.\n* Study participant unwilling or unable to undergo MRI, including patients with contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc.\n* Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months of screening or total use within the last two years prior to screening of > 3 months.\n* Prostate volume more than 80 cc at prior MRI imaging.\n* International Prostate Symptom Score â‰¥ 20.",
    "miscellaneous_criteria": ""
}